The effect of papaverine on morphologic differentiation, proliferation and invasive potential of human prostatic cancer LNCaP cells

International Journal of Urology

Volumn 6, Issue 6, 1999, Pages 314-319

  Goto, Toshitaka ^a,b,c   Matsushima, Hisashi ^b   Kasuya, Yutaka ^b   Hosaka, Yoshio ^b   Kitamura, Tadaichi ^b   Kawabe, Kazuki ^b   Hida, Akino ^a   Ohta, Yasuyuki ^a   Simizu, Takahisa ^a   Takeda, Ken ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NONE   (Japan)

Author keywords

Cyclic AMP; Differentiation; LNCaP; Papaverine; Phosphodiesterase inhibitor; Prostate cancer

Indexed keywords

CYCLIC AMP; ISOBUTYLMETHYLXANTHINE; MATRIGEL; PAPAVERINE; PHOSPHODIESTERASE INHIBITOR; THEOPHYLLINE;

ARTICLE; CANCER INVASION; CELL COUNT; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOASSAY;

EID: 0033052395     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.1999.00069.x     Document Type: Article

References (23)

1. 1 Huggins C, Hodges CV. Studies on prostatic cancer. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293-7.
2. 2 Gittes RF. Carcinoma of the prostate. N. Engl. J. Med. 1991; 324: 236 45.
3. 3 Bloch A. Induced cell differentiation in cancer therapy. Cancer Treat. Rep. 1984; 68: 199-205.
4. 4 Muindi JR, Frankel GE, Huselton C et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer 1992; 52: 2138-42.
5. 5 Dahiya R, Park HD, Cusick J, Vessella RL, Fournier G, Narayan P. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int. J. Cancer 1994; 59: 126-32.
6. 6 Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952-60.
7. 7 Friedman DL. Role of cyclic nucleotides in cell growth and differentiation. Physiol. Rev. 1976; 56: 652-708.
8. 8 Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: New approaches to therapy. Cancer Res. 1990; 50: 7093-100.
9. 9 Kuo JF, Greengard P. Cyclic nucleotide-dependent protein kinases. ∂. Widespread occurrence of adenosine 3':5'-monophosphate-dependent protein kinase in various tissue and phyla of the animal kigdom. Proc. Natl. Acad. Sci. USA 1969; 64: 1349-55.
10. 10 Trepel JB, Colamonici OR, Kelly K et al. Transcriptional inactivation of c-myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells. Mol. Cell Biol. 1987; 7: 2644-8.
11. 11 Bang YJ, Kim SJ, Danielpour D et al. Cyclic AMP induces transforming growth factorɿ2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. Proc. Natl. Acad. Sci. USA 1992: 89: 3556-60.
12. 12 Iwamoto Y, Reich R, Nemeth G, Yamada Y, Martin GR. Cyclic AMP decreases chemotaxis, invasiveness and lung colonization of H-ras transformed mouse fibroblasts. Clin. Exp. Metastasis 1993; 11: 492-501.
13. 13 Tanaka K, Iwamoto Y, Ito Y et al. Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer Res. 1995; 55: 2927-35.
14. 14 Boghaert ER, Simpson J, Jacob RJ, Lacey T, Walsh JW, Zimmer SG. The effect of dibutyryl cAMP (dBcAMP) on morphological differentiation, growth and invasion in vitro of a hamster brain-tumor cell line: A comparative study of dBcAMP effects in 2-and 3-dimensional cultures. Int. J. Cancer 1991; 47: 610-8.
15. 15 Bang YJ, Pirnia F, Fang WG et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc. Natl. Acad. Sci. USA 1994; 91: 5330-4.
16. 16 Appleman MM, Thompson WJ, Russel TR. Cyclic nucleotide phosphodiesterases. Adv. Cyclic Nucleotide Res. 1973; 3: 65-98.
17. 17 Sugimoto T, Sawada T, Matsumura T et al. Morphological differentiation of human neuroblastoma cell lines by new synthetic polyprenoic acid (E5166). Cancer Res. 1987; 47: 5433-8.
18. 18 Honma M, Satoh T, Takezawa J, Ui M. An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue. Biochem. Med. 1977, 18: 257-73.
19. 19 Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 1982; 2: 938.
20. 20 Prasad KN, Kumar S. Role of cyclic AMP in differentiation of human neuroblastoma cells in culture. Cancer 1975; 36: 1338-43.
21. 21 Nakajima F, Imashuku S, Green AA. Characterisation and activation of cyclic adenosine 3',5'-monophosphate dependent protein kinase in C1300 murine neuroblastoma clones growing in vivo. Int. J. Cancer 1982; 30: 805-12.
22. 22 Helson L, Helson C, Peterson RF, Das SK. A rationale for the treatment of metastatic neuroblastoma. J. Natl. Cancer Inst. 1976; 57: 727-9.
23. 23 Stephenson RA, Dinney CPN, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst. 1992; 84: 951-7.